Related Experiment Video
Updated: Oct 23, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Recent Advances in ALK2 Inhibitors
1Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.
Activin receptor-like kinase-2 (ALK2) inhibitors show promise for treating fibrodysplasia ossificans progressiva (FOP) and diffuse intrinsic pontine glioma (DIPG). Structural features and in vivo data support their potential for treating peripheral or CNS diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Activin receptor-like kinase-2 (ALK2) is a crucial type I bone morphogenetic protein (BMP) receptor involved in bone, heart, and brain development.
- Gain-of-function mutations in ALK2 are implicated in fibrodysplasia ossificans progressiva (FOP) and diffuse intrinsic pontine glioma (DIPG).
Purpose of the Study:
- To review the structural characteristics of ALK2 inhibitors that enhance potency and selectivity.
- To evaluate pharmacokinetic and in vivo efficacy data for ALK2 inhibitors in treating peripheral and central nervous system (CNS) diseases.
Main Methods:
- Literature review of structural biology studies on ALK2 inhibitors.
- Analysis of preclinical pharmacokinetic and in vivo efficacy data for ALK2 inhibitors.
Main Results:
- Key structural features contributing to ALK2 inhibitor potency and selectivity have been identified.
- Pharmacokinetic profiles and in vivo efficacy data suggest ALK2 inhibitors' potential for treating FOP and DIPG.
Conclusions:
- ALK2 inhibitors represent a promising targeted therapeutic strategy for FOP and DIPG.
- Further investigation into the pharmacokinetic and in vivo efficacy of ALK2 inhibitors is warranted for CNS and peripheral disease treatment.
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Alkynes to Aldehydes and Ketones: Hydroboration-Oxidation
One of the convenient methods for the preparation of aldehydes and ketones is via hydration of alkynes. Hydroboration-oxidation of alkynes is an indirect hydration reaction in which an alkyne is treated with borane followed by oxidation with alkaline peroxide to form an enol that rapidly converts into an aldehyde or a ketone. Terminal alkynes form aldehydes, whereas internal alkynes give ketones as the final product.
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
FDA Approved Drugs: Changes to Approved Drugs
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Direct-Acting Cholinergic Agonists: Pharmacokinetics

